Skip to content

Cannabis and Seniors

Cannabis and Seniors

As more and more research comes out regarding the medical benefits of cannabis, it’s important to keep up with new research as it becomes available.  Here at Arfinn Med, we constantly review new studies and look at our own deidentified efficacy data to try to find any additional insights we can relay to our registered users. With that in mind, we took a closer look at research coming out of the University of Illinois and the University of Iowa regarding the medicinal benefit of cannabis on Seniors.

The research found “strong positive association” between the frequency of cannabis use by Seniors and self-reported improvements in pain, health-care utilization, and overall health-related quality of life. The researchers revealed they had “identified a strong positive association between higher frequency of cannabis use and improvement to HRQL and HCU [health-care utilization] scores.”

With many clinics seeing an increase in the amount of Seniors turning to medical cannabis, we wanted to identify some additional trends through querying our database of deidentified data for patient demographics 60 and above.

Similar to what this report indicated, we found that Seniors self-reported an average 3.7 resolution of symptoms which translates on our scale to just below a ‘significant resolution’ of symptoms. In addition to the overall efficacy, we found that chronic pain was the most frequently sited qualifying condition with both THC dominant and balanced ratios of THC and CBD being the most frequently used cannabis profiles.  Lastly, in terms of mode of consumption, tinctures were the preferred route.

If you are interested in learning more about the efficacy of medical cannabis and would like to add our electronic medical record (EMR), practice management, and telehealth platform to your practice, please schedule a quick demo by contacting info@arfinnmed.com or by clicking here!

Stories you may be interested in

States with medical marijuana laws saw 20 percent drop in some opioid prescriptions

States with active medical marijuana laws saw certain opioid prescription rates drop nearly 20 percent compared to states without medical marijuana programs, according to a first-of-its-kind study out of Columbia University’s Irving Medical Center. Authors said the findings underscore the importance of providing patients with pain management alternatives, such as cannabis, in efforts to reduce…
Read More

PTSD and Cannabis

Post-Traumatic Stress Disorder (PTSD) is a psychiatric disorder that occurs in people who witnessed or have gone through a traumatic event.  That can include events such as  natural disasters, war/combat, a serious accident, or personal assault, among others.  People suffering from PTSD have disturbing thoughts and feelings related to the traumatic event that can last…
Read More

Insomnia: A Silent Epidemic

The struggle to get a good night’s sleep is something many adults can relate to, but what if there was a natural alternative to keep those sheep jumping all night long? CBD, also known as cannabidiol, has been gaining popularity among patients to help treat pain, anxiety and so much more. Additionally, conditions such as…
Read More

Research shows cannabis can lower opioid dosage, but studies are preliminary

Larson cited one statistic to justify his bill: “Studies have shown up to 75% reduction in opioid dosage for medical cannabis users” The intersection of medical cannabis and opioid use as treatments for chronic pain is an emerging field of research as more states loosen regulations on medical and recreational use of marijuana. But does…
Read More

Three Key Voices in the Medical Marijuana Industry

As medical marijuana programs continue to expand throughout the United States, it is important to recognize some of the key voices throughout the industry that got us here. These individuals range from researches to physicians and even to patients who started their own advocacy group. Keep reading to learn about just three of the many…
Read More

Colorado’s first licensed cannabis R&D firm to study marijuana’s effect on Alzheimer’s disease

A Denver-based company hopes to be the state’s first to study the effects of marijuana on Alzheimer’s disease, thanks to a newly available research and development license in the city. MedPharm Holdings plans to apply for a Denver marijuana R&D license to test delta-9 tetrahydrocannabinol (THC), cannabidiol (CBD) and other cannabinoids’ effects on Alzheimer’s and…
Read More

Leave a Comment

You must be logged in to post a comment.